Literature DB >> 3698914

Dissimilarities between the uterine estrogen receptor in cytosol of castrated and estradiol-treated rats.

J C Faye, A Fargin, F Bayard.   

Abstract

The estrogen receptor (ER) in its native state appears oligomeric and can be dissociated by salt into a monomer with a mol wt of 50,000-80,000. Lower molecular weight fragments have also been observed but are considered to result from ER proteolysis by tissue proteases. Three-month-old Sprague-Dawley rats have been studied after castration, estradiol treatment (3 days at 25 micrograms/day), or during the normal estrus cycle. The uterine cytosol was labeled with [3H]estradiol, and the [3H]estradiol-receptor complexes were studied by sucrose gradient centrifugation, gel filtration, diethylaminoethyl (DEAE)-Trisacryl and phosphocellulose chromatography, and kinetic experiments. In low salt buffer in presence of molybdate (20 mM), uterine ER of castrated and treated rats could not be differentiated by sucrose gradient centrifugation (9.9S), gel filtration (7.7 nm), or DEAE-Trisacryl and phosphocellulose chromatography, but the dissociation rate at 23 C was lower for castrated than for treated rats (t1/2 = 45 and 27 min, respectively). In high salt buffer (0.4 M KCl) in presence of molybdate (20 mM), no difference was apparent by sucrose gradient centrifugation (3.7S) or gel filtration (3.4 nm), but again the dissociation rate at 23 C was lower for castrated than for treated rats (t1/2 = 102 and 45 min, respectively). In high salt buffer in presence of molybdate and ammonium thiocyanate (0.5 M), differences were observed by sucrose gradient centrifugation (3.6 and 3.2S), gel filtration (3.2 and 2.6 nm), and dissociation rate assays at 10 C (t1/2 = 24 and 12 min) for castrated and treated rats. The calculated wts were 50,000 and 35,000, respectively. Protection from limited proteolysis by molybdate, contained in all buffers used, plus various protease inhibitors, particularly leupeptin, as well as mixing tissues before homogenization, suggested that the 35,000-dalton monomer was not a product of protease action formed after cell breakage. ERs covalently labeled with [3H]tamoxifen aziridine also showed different entities of 62,000 and 47,000 mol wts, respectively, on denaturing polyacrylamide gels. In vitro activation and transformation were demonstrated for the two types of [3H]estradiol-receptor complexes by sucrose gradient centrifugation analysis and affinity for phosphocellulose and purified nuclei. Finally, it has been shown that both entities coexisted in different proportions during the diestrous (1:2) and proestrous (1:1) phases of the estrus cycle; only the low mol wt component was present during the estrous phase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3698914     DOI: 10.1210/endo-118-6-2276

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Cell-specific mechanisms of estrogen receptor in the pituitary gland.

Authors:  F Demay; S Geffroy; C Tiffoche; M de Monti; M L Thieulant
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

2.  The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice.

Authors:  C Pendaries; B Darblade; P Rochaix; A Krust; P Chambon; K S Korach; F Bayard; J F Arnal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

3.  Transcriptional complexes engaged by apo-estrogen receptor-alpha isoforms have divergent outcomes.

Authors:  Raphaël Métivier; Graziella Penot; Richard P Carmouche; Michael R Hübner; George Reid; Stefanie Denger; Dominique Manu; Heike Brand; Martin Kos; Vladimir Benes; Frank Gannon
Journal:  EMBO J       Date:  2004-09-02       Impact factor: 11.598

4.  65 and 47 kDa forms of estrogen receptor in human breast cancer: relation with estrogen responsiveness.

Authors:  S Jozan; A M Julia; A Carretie; N Eche; V Maisongrosse; B Fouet; B Marques; J F David
Journal:  Breast Cancer Res Treat       Date:  1991-10       Impact factor: 4.872

5.  Truncated forms of DNA-binding estrogen receptors in human breast cancer.

Authors:  G K Scott; P Kushner; J L Vigne; C C Benz
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.